AMENDMENT UNDER 37 C.F.R. § 1.114(c)

U.S. Application No.: 09/844,679

Attorney Docket No.: Q64172

REMARKS

Claims 1-9 are all the claims pending in the application. Claims 1 and 9 have been

amended based on the disclosure in Figs. 6 and 7 and pages 26-27 in the specification. Claim 9

has also been placed in independent form.

Entry of the above amendments is respectfully requested.

Based on the concentration ranges of the iridium complex compound recited in the

amended claims, Applicants submit that the amended claims are novel and unobvious over the

cited art, and thus withdrawal of the anticipation and obviousness rejections set forth in the

Office Action of April 11, 2003 is respectfully requested.

In view of the above, reconsideration and allowance of this application are now believed

to be in order, and such actions are hereby solicited. If any points remain in issue which the

Examiner feels may be best resolved through a personal or telephone interview, the Examiner is

kindly requested to contact the undersigned at the telephone number listed below.

The USPTO is directed and authorized to charge all required fees, except for the Issue

Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any

overpayments to said Deposit Account.

Respectfully submitted,

Registration No. 33,725

Bruce E. Kramer

nuc. S. Krame

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: October 14, 2003

5